ESC 22: Hot Line & Late-breaking Science Video Collection

  • Published:  24 August 2022
  • Views: 

    Views Icon

    6610

  • Likes: 

    Heart Icon

    3

Up Next

ESC 22: Hot Line & Late-breaking Science Video Collection

  • Published:  24 August 2022
  • Views: 

    Views Icon

    6610

  • Likes: 

    Heart Icon

    3

Average (ratings)
No ratings
Your rating
Overview

What's hot at European Society of Cardiology (ESC) Congress 22?

Stay tuned and browse our curated coverage of the latest data in cardiology. 

  • For a concise line up of the most awaited trials join Prof Nicolas Van Mieghem and Dr Joost Daemen and their regular View From the Thoraxcenter series. 
  • For a deeper dive into key clinical trial data and applicability, host, Dr Harriette Van Spall talks with principal investigators in her Late-Breaker Discussion Series
  • Short, accessible Expert Interviews conducted with select faculty focusing on data, patient care and the future of their field. 
  • To mark the release of the new ESC Guidelines on Cardio-Oncology, we will feature a 10-minute summary and a 10-minute live audience Q&A.
  • We asked some of the most prominent researchers today about their pathways in the Behind the Heart series.

Watch our Radcliffe Premiere TV to be transported to Barcelona. 

More from this programme

Part 3

ESC Guidelines on Cardio-Oncology: Summary & Question Time

Faculty Biographies

Marco Valgimigli

Marco Valgimigli

Deputy Chief of Cardiology

Prof Marco Valgimigli is an Interventional Cardiologist and Deputy Chief of Cardiology at the Cardiocentro Ticino Institute in Lugano, Switzerland.

He obtained his medical degree from the University of Bologna, and completed his training in internal medicine at the same university. He received a degree in cardiological sciences at the University of Ferrara and a PhD in interventional cardiology at Erasmus Medical Center in Rotterdam.

Prof Valgimigli’s areas of research are wide ranging and include high-risk percutaneous interventions (PCI); invasive treatment of myocardial ischaemia (MI); reparative medicine with adult stem cells during MI and heart failure; antithrombotic therapy during and after PCI; and prognostic stratification during acute coronary syndromes and MI.

View full profile